8-K: Tango Therapeutics Halts TNG348 Program Due to Liver Toxicity, Focuses on PRMT5 and CoREST

Tango Therapeutics has discontinued its TNG348 program due to liver toxicity observed in patients during a Phase 1/2 clinical trial, shifting focus to its PRMT5 and CoREST programs.

Summary

• Tango Therapeutics has decided to discontinue the development of its TNG348 program, a USP1 inhibitor, due to liver toxicity observed in patients during a Phase 1/2 clinical trial.
• The decision was made after observing Grade 3/4 liver function abnormalities in patients who remained on the study for more than eight weeks.
• No patients had yet received the combination of TNG348 and olaparib, a PARP inhibitor, which was also part of the study.
• The company will now focus its resources and capital on its existing portfolio, particularly the PRMT5 program.
• Tango Therapeutics expects to provide a comprehensive clinical update on TNG908 and TNG462 in the second half of this year.
• The company's cash runway is extended into 2027.

Sentiment

Score: 4

Explanation: The discontinuation of a clinical program due to toxicity is a significant negative, but the company's focus on other programs and extended cash runway provide some positive aspects. The overall sentiment is cautiously negative.

Positives

• The company is prioritizing patient safety by discontinuing the TNG348 program due to observed toxicity.
• Tango Therapeutics is focusing resources on its PRMT5 program, which remains on track.
• The company's cash runway is extended into 2027, providing financial stability.
• Tango Therapeutics plans to provide a clinical update on TNG908 and TNG462 in the second half of this year.

Negatives

• The TNG348 program, a USP1 inhibitor, has been discontinued due to liver toxicity.
• Grade 3/4 liver function abnormalities were observed in patients during the TNG348 clinical trial.
• The discontinuation of the TNG348 program represents a setback in the company's pipeline.

Risks

• The company's pipeline products may not be safe or effective in humans.
• Tango has a limited operating history and has not generated any revenue to date from product sales.
• The company may need to raise capital in the future, and if unable to do so, may have to delay or discontinue development programs.
• The company's approach to drug discovery is novel and unproven, making it difficult to predict the time and cost of development.
• The company is dependent on third parties for conducting clinical trials and producing drug substance and drug product.
• Government regulations may negatively impact the company's business.

Future Outlook

Tango Therapeutics plans to focus on its existing portfolio, particularly the PRMT5 program, and expects to provide a clinical update on TNG908 and TNG462 in the second half of this year. The company's cash runway is extended into 2027.

Management Comments

• Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, stated that patient safety is the first priority and the decision to discontinue TNG348 was made due to liver toxicity.
• Management believes discontinuing TNG348 is the right decision given the data at hand.
• Management has stated they will focus resources and capital on the existing portfolio, particularly the PRMT5 program.

Industry Context

The discontinuation of a clinical program due to toxicity is not uncommon in the biotechnology industry, highlighting the inherent risks in drug development. Tango's decision to prioritize other programs and extend its cash runway is a strategic move to maintain focus and financial stability.

Comparison to Industry Standards

• The discontinuation of a drug program due to toxicity is a common occurrence in the biotech industry, with many companies facing similar setbacks during clinical trials.
• Companies like Gilead Sciences and Vertex Pharmaceuticals have also experienced program terminations due to safety concerns, highlighting the challenges in drug development.
• Tango's decision to focus on its PRMT5 program is similar to other biotech companies that prioritize their most promising assets after setbacks.
• The extension of the cash runway into 2027 is a positive sign, as many biotech companies struggle with funding and require frequent capital raises.

Stakeholder Impact

• Shareholders may react negatively to the discontinuation of the TNG348 program.
• Employees may experience uncertainty due to the program termination.
• Patients who were participating in the TNG348 trial will no longer have access to the treatment.

Next Steps

• Tango Therapeutics will focus resources on its PRMT5 program.
• The company plans to provide a clinical update on TNG908 and TNG462 in the second half of this year.

Key Dates

Keywords

Tango Therapeutics, TNG348, USP1 inhibitor, liver toxicity, clinical trial, PRMT5 program, TNG908, TNG462, cancer medicines, biotechnology